GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc (the 'Company').
On 31 December 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £13.83 per Ordinary Share, and notional ADSs at a price of $40.98 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 October 2015 to 31 December 2015:
Non Executive Director |
Ordinary Shares |
No. of ADSs |
Sir Philip Hampton |
3,163.413 |
|
Professor Sir Roy Anderson |
655.278 |
|
Vindi Banga |
1,536.515 |
|
Dr Stephanie Burns |
|
410.403 |
Stacey Cartwright |
519.704 |
|
Lynn Elsenhans |
|
912.543 |
Judy Lewent |
|
398.332 |
Sir Deryck Maughan |
|
1,110.502 |
Dr Daniel Podolsky |
|
832.877 |
Urs Rohner |
610.087 |
|
Hans Wijers |
519.704 |
|
|
|
|
In addition, on 31 December 2015, Mr Banga was allocated 566.213 notional Ordinary Shares at a price of £12.51 per Ordinary Share in respect of the period of service from 1 September 2015 to 30 September 2015.
The Company and the Non-Executive Directors were informed of these allocations on 4 January 2016.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
4 January 2016